Annapolis Financial Services’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-9
Closed 470
2022
Q1
$0 Hold
9
﹤0.01% 481
2021
Q4
$0 Hold
9
﹤0.01% 481
2021
Q3
$0 Hold
9
﹤0.01% 452
2021
Q2
$0 Buy
+9
New +$422 ﹤0.01% 439

Other funds holding IDNA

Annapolis Financial Services's IDNA Position: Q2 2022 in Review

Annapolis Financial Services sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2022, closing a stake of 9 shares.

Annapolis Financial Services first reported a position in IDNA in Q2 2021 and held it in 4 quarters. The position peaked at $0 in Q1 2022. 73 funds tracked by Wall St. Rank hold IDNA as of Q2 2022.

  • Annapolis Financial Services reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2022 after selling out during the quarter.
  • Annapolis Financial Services sold 9 iShares Genomics Immunology and Healthcare ETF shares in Q2 2022.
  • Annapolis Financial Services first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2021 and held it in 4 quarters.
  • Annapolis Financial Services's iShares Genomics Immunology and Healthcare ETF position peaked at $0 in Q1 2022.
  • 73 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2022.

Based on Annapolis Financial Services's 13F filing for Q2 2022, filed 22 Jul 2022.